LGND vs. IRWD, MNKD, INVA, DVAX, OPK, ARCT, NRIX, PRAX, GERN, and CMPS
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), MannKind (MNKD), Innoviva (INVA), Dynavax Technologies (DVAX), OPKO Health (OPK), Arcturus Therapeutics (ARCT), Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Geron (GERN), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry.
Ironwood Pharmaceuticals (NASDAQ:IRWD) and Ligand Pharmaceuticals (NASDAQ:LGND) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Ligand Pharmaceuticals has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ironwood Pharmaceuticals currently has a consensus target price of $19.80, suggesting a potential upside of 154.50%. Ligand Pharmaceuticals has a consensus target price of $116.33, suggesting a potential upside of 65.11%. Given Ligand Pharmaceuticals' higher probable upside, equities research analysts clearly believe Ironwood Pharmaceuticals is more favorable than Ligand Pharmaceuticals.
91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 13.1% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 10.4% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Ironwood Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.
In the previous week, Ligand Pharmaceuticals had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 3 mentions for Ligand Pharmaceuticals and 2 mentions for Ironwood Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.76 beat Ironwood Pharmaceuticals' score of 0.17 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.
Ligand Pharmaceuticals received 27 more outperform votes than Ironwood Pharmaceuticals when rated by MarketBeat users. Likewise, 69.92% of users gave Ligand Pharmaceuticals an outperform vote while only 61.04% of users gave Ironwood Pharmaceuticals an outperform vote.
Ligand Pharmaceuticals has a net margin of 37.80% compared to Ligand Pharmaceuticals' net margin of -226.37%. Ironwood Pharmaceuticals' return on equity of 11.98% beat Ligand Pharmaceuticals' return on equity.
Summary
Ligand Pharmaceuticals beats Ironwood Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
